The gut-kidney axis: Indoxyl sulfate, p-cresyl sulfate and CKD progression

Nephrology Dialysis Transplantation

Volumn 26, Issue 3, 2011, Pages 759-761

  Meijers, Björn K I ^a   Evenepoel, Pieter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 CRESYL SULFATE; ALBUMIN; AST 120; CREATININE; INDICAN; UNCLASSIFIED DRUG; UREA; UREMIC TOXIN;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIALYSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; FERMENTATION; FOOD INTAKE; GLOMERULUS FILTRATION RATE; HYDROXYLATION; LARGE INTESTINE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; REVIEW; UREMIA;

CHRONIC DISEASE; CRESOLS; DISEASE PROGRESSION; HUMANS; INDICAN; KIDNEY DISEASES; SULFURIC ACID ESTERS;

EID: 79952154288     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq818     Document Type: Review

References (26)

1. Cushny A. The Secretion of the Urine. London: Longmann & Green, 1917;1-241
2. Meyer TW, Hostetter TH. Uremia. N Engl J Med 2007;357:1316-1325
3. Vanholder R, De Smet R, Glorieux G et al. Review on uraemic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943 (Pubitemid 36513344)
4. Meyer TW, Leeper EC, Bartlett DW et al. Increasing dialysate flow and dialyzer mass transfer area coefficient to increase the clearance of protein-bound solutes. J Am Soc Nephrol 2004;15:1927-1935 (Pubitemid 38822074)
5. Evenepoel P, Meijers BKI, Bammens BRM et al. Uraemic toxins originating from colonic microbial metabolism. Kidney Int 2009;76: S12-S19
6. Bammens B, Evenepoel P, Keuleers H et al. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006;69:1081-1087 (Pubitemid 43372184)
7. Meijers BKI, Bammens B, De Moor B et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008;73:1174-1180 (Pubitemid 351620433)
8. Liabeuf S, Barreto DV, Barreto FC et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010;25:1183-1191
9. Meijers BKI, Claes K, Bammens B et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010;5:1182-1189
10. Barreto FC, Barreto DV, Liabeuf S et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:1551-1558
11. Wikoff WR, Anfora AT, Liu J et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 2009;106:3698-3703
12. Martinez AW, Recht NS, Hostetter TH et al. Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005;16:3430-3436 (Pubitemid 46187553)
13. de Loor H, Bammens B, Evenepoel P et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uraemic and normal serum. Clin Chem 2005;51:1535-1538 (Pubitemid 41060897)
14. de Loor H, Meijers BKI, Meyer TW et al. Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uraemic and normal serum during sample preparation followed by fluorescence liquid chromatography. J Chromatogr 2009;1216:4684-4688
15. Meijers BKI, de Loor H, Bammens B et al. p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:1932-1938
16. Niwa T, Nomura T, Sugiyama S et al. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uraemic patients. Kidney Int 1997;52: S23-S28 (Pubitemid 27489396)
17. Schepers E, Glorieux G, Vanholder R. The gut: the forgotten organ in uremia?. Blood Purif 2010;29:130-136
18. Niwa T, Ise M. Indoxyl sulfate, a circulating uraemic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994;124:96-104 (Pubitemid 2125685)
19. Niwa T. Organic acids and the uraemic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol 1996;3:167-182
20. Niwa T. Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr 2010;20: S2-S6
21. Tumur Z, Shimizu H, Enomoto A et al. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am J Nephrol 2010;31:435-441
22. Iida S, Kohno K, Yoshimura J et al. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure. Clin Exp Nephrol 2006;10:262-267 (Pubitemid 46012955)
23. Akizawa T, Asano Y, Morita S et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 2009;54:459-467
24. Schulman G, Agarwal R, Acharya M et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006;47:565-577
25. Kikuchi K, Itoh Y, Tateoka R et al. Metabolomic search for uraemic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:2997-3002
26. Meijers BK, De Preter V, Verbeke K et al. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 2010;25:219-224